H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Protara Therapeutics today and set a price target of $23.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andres Y. Maldonado has given his Buy rating due to a combination of factors including promising interim data from the Phase 2 STARBORN-2 trial for TARA-002, which showed strong responses in patients with lymphatic malformations (LMs). The trial results indicated that a significant percentage of patients achieved complete or substantial reduction in LM volume, with no serious adverse events reported, highlighting the potential of TARA-002 as a safe and effective treatment.
Furthermore, the data supports the planning of pivotal trials and aligns with historical evidence of efficacy and safety, reinforcing confidence in TARA-002’s potential as a foundational therapy for pediatric vascular anomalies. The promising outcomes, combined with the strategic preparation for commercial execution, underpin the Buy rating and the $23 price target, as they suggest a de-risked LM program and a strong potential for sustainable value creation.
In another report released on November 17, LifeSci Capital also maintained a Buy rating on the stock with a $26.00 price target.